

Product Data Sheet

Product Name: Anagrelide-13C3

Cat. No.: GC48870

Chemical Properties

Cas. No.

SMILES C1C=C([13CH2]N([13CH2]2)C(N3)=N[13C]2=O)C3=CC=C1Cl

Formula C7[13C]3H7Cl2N3O

M.Wt 259.1


Solubility DMSO: soluble

Storage -20°C

General tips For obtaining a higher solubility, please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution: ship with blue ice. All other available size: ship with RT, or blue ice upon request.

Structure



Background

Anagrelide-¹³C₃ is intended for use as an internal standard for the quantification of anagrelide by GC- or LC-MS. Anagrelide is an inhibitor of phosphodiesterase 3 (PDE3; IC₅₀ = 36 nM for the human platelet enzyme).¹ It inhibits thrombopoietin-induced megakaryocytopoiesis of isolated human CD34⁺ progenitor cells (IC₅₀ = 26 nM).² Anagrelide reduces platelet aggregation induced by ADP, collagen, thrombin, or arachidonic acid in isolated rabbit platelet rich-plasma (EC₅₀s = 0.31, 0.08, 0.18, and 0.1 µg/ml, respectively).³ It inhibits platelet thrombus formation in a dog model of electrically induced carotid artery thrombosis when administered at doses ranging from 0.5 to 5 mg/kg.⁴ Formulations containing anagrelide have been used in the treatment of thrombocythemia.

1. Wang, G., Franklin, R., Hong, Y., et al. Comparison of the biological activities of anagrelide and its

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

major metabolites in haematopoietic cell cultures Br. J. Pharmacol. 146(3)324-332(2005) 2. Hong, Y., Wang, G., Gutierrez del Arroyo, A., et al. Comparison between anagrelide and hydroxycarbamide in their activities against haematopoietic progenitor cell growth and differentiation: Selectivity of anagrelide for the megakaryocytic lineage Leukemia 20(6)1117-1122(2006) 3. Fleming, J.S., and Buyniski, J.P. A potent new inhibitor of platelet aggregation and experimental thrombosis, anagrelide (BL-4162A) Thromb. Res. 15(3-4)373-388(1979) 4. Fleming, J.S., and Buyniski, J.P. Anagrelide New drugs annual: Cardiovascular drugs 277-294(1983)

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA